Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Interactomes of Glycogen Synthase Kinase-3 Isoforms. | J Proteome Res | 2023 | 36779422 | PubTator, text mining | PubMed |
| Circular RNAs as a Diagnostic and Therapeutic Target in Cardiovascular Diseases. | Int J Mol Sci | 2023 | 36768449 | PubTator, text mining | PubMed |
| The Critical Impact of Sphingolipid Metabolism in Breast Cancer Progression and Drug Response. | Int J Mol Sci | 2023 | 36768427 | PubTator, text mining | PubMed |
| The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches. | Int J Mol Sci | 2023 | 36768342 | PubTator, text mining | PubMed |
| The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21). | Cells | 2023 | 36766699 | PubTator, text mining | PubMed |
| Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates. | Cancers (Basel) | 2023 | 36765727 | PubTator, text mining | PubMed |
| Integrated analysis of RNA methylation regulators crosstalk and immune infiltration for predictive and personalized therapy of diabetic nephropathy. | Hum Genomics | 2023 | 36765416 | PubTator, text mining | PubMed |
| METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer. | Breast Cancer Res | 2023 | 36765397 | PubTator, text mining | PubMed |
| Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. | Front Immunol | 2023 | 36761737 | PubTator, text mining | PubMed |
| Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. | Cell Death Discov | 2023 | 36759501 | PubTator, text mining | PubMed |
| Editorial: New molecular targets involved in lung adenocarcinoma. | Front Endocrinol (Lausanne) | 2023 | 36755924 | PubTator, text mining | PubMed |
| THADA-IGF2BP3 fusions detected in fine-needle aspiration specimens of thyroid nodules: An institutional experience. | Diagn Cytopathol | 2023 | 36752652 | PubTator, text mining | PubMed |
| Hsa_circ_0063329 inhibits prostate cancer growth and metastasis by modulating the miR-605-5p/tgif2 axis. | Cell Cycle | 2023 | 36740902 | PubTator, text mining | PubMed |
| Interaction between N6-methyladenosine (m6A) modification and environmental chemical-induced diseases in various organ systems. | Chem Biol Interact | 2023 | 36736874 | PubTator, text mining | PubMed |
| Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma. | J Transl Med | 2023 | 36732815 | PubTator, text mining | PubMed |
| IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer. | BMC Cancer | 2023 | 36732736 | PubTator, text mining | PubMed |
| Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. | Nat Commun | 2023 | 36720864 | PubTator, text mining | PubMed |
| The miR-27a-3p/FTO axis modifies hypoxia-induced malignant behaviors of glioma cells. | Acta Biochim Biophys Sin (Shanghai) | 2023 | 36718644 | PubTator, text mining | PubMed |
| Cell Cycle-Related Gene SPC24: A Novel Potential Diagnostic and Prognostic Biomarker for Laryngeal Squamous Cell Cancer. | Biomed Res Int | 2023 | 36718148 | PubTator, text mining | PubMed |
| Differential Plasma Proteins Identified via iTRAQ-Based Analysis Serve as Diagnostic Markers of Pancreatic Ductal Adenocarcinoma. | Dis Markers | 2023 | 36712921 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=42